BioCentury
ARTICLE | Clinical News

APTO-253: Phase Ib hold

September 19, 2016 7:00 AM UTC

Aptose said it submitted a formal response to FDA’s requests following a November 2015 clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The ...